Novo Nordisk subpoenaed in US over marketing
Wednesday, February 16, 2011
COPENHAGEN, Denmark (AP) — Novo Nordisk A/S says it has been subpoenaed by the U.S. Attorney for the District of Massachusetts in an investigation of how the Danish pharmaceutical company markets three diabetes drugs.
Novo Nordisk says it will cooperate in the investigation, which involves “potential criminal offenses relating to the company’s marketing and promotion practices” for NovoLog, Levemir and Victoza.
The Copenhagen, Denmark-based company said Wednesday it “cannot determine or predict the outcome of this matter or assess the consequences thereof.”
Novo Nordisk is the world’s biggest maker of insulins.
Use the comment form below to begin a discussion about this content.
Please review our Policies and Procedures before registering or commenting